Hagop Kantarjian, Professor and Chair of the Department of Leukemia at The University of Texas MD Anderson Cancer Center, shared a post on X:
“Dasatinib and Venetoclax is safe and effective in newly diagnosed Chronic Myeloid Leukaemia in CP, but no better than single-agent Dasatinib, longer follow-up needed to evaluate impact on TFR.”
Additional information.
Source: Hagop Kantarjian/X
